Abstract | BACKGROUND & AIMS: Limited data have shown high efficacy of co-formulated ombitasvir/ paritaprevir/ ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stages 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1- and 4-infected patients. METHODS: In this observational cohort (n = 67), we enrolled stages 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n = 32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n = 35, including 3 with GT1/4 co-infection). RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily. Primary endpoints were SVR12, calculated on intention-to-treat (ITT) basis, and occurrence of serious adverse events. RESULTS: The mean age of the cohort was 45.7 ± 12.7 years, 50.7% were females, 20.9% had cirrhosis, 35.8% were treatment-experienced and 97% were on haemodialysis. Three patients (F4) received 24-week treatment, 2 with GT4, and 1 with GT1a; and 19.4% were treated without RBV, including 9 GT1, and 4 GT4. Overall, 65 (97.1%) patients achieved SVR12, including 100% of those with a post-treatment follow-up (modified ITT analysis). Of the two patients without SVR12, one died from sepsis-related complications and the other from a myocardial infarction 2 weeks after completing therapy. Grades 3-4 anaemia occurred in 8.9%. CONCLUSION: A 12-week regimen of OBV/PTV/r ± DSV with or without RBV is highly effective with a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. SVR12 rates were high regardless of patient characteristics.
|
Authors | Faisal M Sanai, Abdullah S Alghamdi, Ahmad A Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M Assiri, Mohamed A Babatin |
Journal | Liver international : official journal of the International Association for the Study of the Liver
(Liver Int)
Vol. 38
Issue 8
Pg. 1395-1401
(08 2018)
ISSN: 1478-3231 [Electronic] United States |
PMID | 29288514
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Anilides
- Antiviral Agents
- Carbamates
- Cyclopropanes
- Lactams, Macrocyclic
- Macrocyclic Compounds
- Sulfonamides
- ombitasvir
- Ribavirin
- Uracil
- Proline
- 2-Naphthylamine
- dasabuvir
- Valine
- Ritonavir
- paritaprevir
|
Topics |
- 2-Naphthylamine
- Adult
- Anilides
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Carbamates
(therapeutic use)
- Cohort Studies
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Hepacivirus
(genetics)
- Hepatitis C, Chronic
(complications, drug therapy)
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis
(virology)
- Macrocyclic Compounds
(therapeutic use)
- Male
- Middle Aged
- Proline
(analogs & derivatives)
- Registries
- Renal Insufficiency, Chronic
(complications)
- Ribavirin
(therapeutic use)
- Ritonavir
(therapeutic use)
- Saudi Arabia
- Sulfonamides
(therapeutic use)
- Sustained Virologic Response
- Uracil
(analogs & derivatives, therapeutic use)
- Valine
|